Paula M Mañán Mejías

Ms. Paula M Mañán Mejías


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HZHan Zhang
Han Zhang
PMPaula M Mañán Mejías
Paula M Mañán Mejías
HMHannah N. Miles
Hannah N. Miles
APAndrea A. Putnam
Andrea A. Putnam
LMLeonard MacGillivray
Leonard MacGillivray
WRWilliam Ricke
William Ricke
The DEAD (Asp-Glu-Ala-Asp)-box helicase 3 X-linked (DDX3X) protein participates in many aspects of mRNA metabolism and stress granule (SG) formation. DDX3X has also been associated with signal transduction and cell cycle regulation that are important in maintaining cellular homeostasis. Malfunctions of DDX3X have been implicated in multiple cancers, including brain cancer, leukemia, prostate cancer, and head and neck cancer. Recently, literature has reported SG-associated cancer drug resistance, which correlates with a negative disease prognosis. Based on the connections between DDX3X, SG formation, and cancer pathology, targeting DDX3X may be a promising direction for cancer therapeutics development. In this review, we describe the biological functions of DDX3X in terms of mRNA metabolism, signal transduction, and cell cycle regulation. Furthermore, we summarize the contributions of DDX3X in SG formation and cellular stress adaptation. Finally, we discuss the relationships of DDX3X, SG, and cancer drug resistance, and discuss the current research progress of several DDX3X inhibitors for cancer treatment.

1 April 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
VPVenkata Sai Usha Sri Polaki
Venkata Sai Usha Sri Polaki
TGTrey E. Gilpin
Trey E. Gilpin
APApoorva T. Patil
Apoorva T. Patil
ECEmily Chiu
Emily Chiu
RBRuth Baker
Ruth Baker
DMDaniel R. Matson
Daniel R. Matson
BACKGROUND: A priori knowledge of recurrence risk in patients with nonmetastatic (International Federation of Gynecology and Obstetrics [FIGO] stage I) uterine serous carcinoma (USC) would enable a risk-stratified approach to the use of adjuvant chemotherapy. This would greatly reduce treatment-related morbidity and be predicted to improve survival. METHODS: GATA2 expression was scored by IHC across a retrospective multiinstitutional cohort of 195 primary USCs. Associations between GATA2 levels and clinicopathologic metrics were evaluated using Student’s t test, Fisher’s exact test, Kaplan-Meier method, and Cox proportional hazard ratio. Invasion in patient-derived USC cells was assessed by Student’s t test. RNA-Seq, anti-GATA2 ChIP-Seq, and confirmatory Western blotting enabled identification of GATA2 targets. RESULTS: Patients with FIGO stage I GATA2 hi USCs had 100% recurrence-free and 100% cancer-related survival, which was significantly better than patients with GATA2 lo USCs. In patients for whom adjuvant chemotherapy was omitted, patients with GATA2 hi USC had 100% recurrence-free 5-year survival compared with 60% recurrence-free survival in patients with GATA2 lo USC. Depletion of GATA2 in patient-derived USC cells increased invasion in vitro. CONCLUSION: Routine GATA2 IHC identifies 33% of patients with FIGO stage I USC who have a greatly reduced risk of posthysterectomy USC recurrence. Our results suggest that a GATA2-guided personalized medicine approach could be rapidly implemented in most hospital settings, would reduce treatment-related morbidity, and would likely improve outcomes in patients with USC. FUNDING: NIH grants R01 DK068634, P30 CA014520, S10 OD023526, K08 DK127244, T32 HL007899, the UW-Madison Department of Pathology and Laboratory Medicine, the UW-Madison Centennial Scholars Program, the Diane Lindstrom Foundation, the American Cancer Society, the V Foundation, The Hartwell Foundation, and the UMN Department of Obstetrics, Gynecology, and Women’s Health.